Journal: PLoS Neglected Tropical Diseases

Article Title: Automated High-Content Assay for Compounds Selectively Toxic to Trypanosoma cruzi in a Myoblastic Cell Line

doi: 10.1371/journal.pntd.0003493

Figure Lengend Snippet: List of compounds used to validate the assay.

Article Snippet: Those compounds not available in GSK chemical collection were purchased from Sigma-Aldrich except the following: amiodarone (Pfizer), cloroxylenol derivative CX1 (Chembridge), dihydroergocristine mesylate (Tocris Bioscience), hydrazide derivative PCH1 (InterBioScreen), LP10 (ChemDiv), loperamide (Enamine), posaconazole ( Sheckchem.com ), pubchem 1473168 and pubchem 3812524 (Bionet), and terconazole (AKSCI-USA).

Techniques:

Journal: PLoS Neglected Tropical Diseases

Article Title: Automated High-Content Assay for Compounds Selectively Toxic to Trypanosoma cruzi in a Myoblastic Cell Line

doi: 10.1371/journal.pntd.0003493

Figure Lengend Snippet: Representative curves of three independent experiments of BNZ, NFX, posaconazole and cyclohexymide normalized activity (%) against T. cruzi amastigotes per compound concentration (M) for each of the three assay outputs: ‘Am/Cell’ (blue), ‘%Infected’ (green) were normalized as described in ; ‘Cells’ (cytotoxic impact of the drugs; yellow) is expressed as percentage of live cells, considering non-treated T. cruzi infected wells as 100%.

Article Snippet: Those compounds not available in GSK chemical collection were purchased from Sigma-Aldrich except the following: amiodarone (Pfizer), cloroxylenol derivative CX1 (Chembridge), dihydroergocristine mesylate (Tocris Bioscience), hydrazide derivative PCH1 (InterBioScreen), LP10 (ChemDiv), loperamide (Enamine), posaconazole ( Sheckchem.com ), pubchem 1473168 and pubchem 3812524 (Bionet), and terconazole (AKSCI-USA).

Techniques: Activity Assay, Concentration Assay, Infection

Journal: Frontiers in Cellular and Infection Microbiology

Article Title: Synergistic effect of pyrvinium pamoate and posaconazole against Cryptococcus neoformans in vitro and in vivo

doi: 10.3389/fcimb.2022.1074903

Figure Lengend Snippet: Galleria mellonella survival curves following infection with Cryptococcus neoformans . Untreated group, uninfected larvae; Saline group, larvae injected with saline; yeast group, larvae infected with C. neoformans without any treatment; POS, C. neoformans -infected larvae treated with posaconazole (POS) alone; POS+PP, C. neoformans -infected larvae treated with POS combined with pyrvinium pamoate (PP); ITR, C. neoformans -infected larvae treated with itraconazole alone; ITR+PP, C. neoformans -infected larvae treated with ITR combined with PP; VOR, C. neoformans -infected larvae treated with voriconazole alone; VOR+PP, C. neoformans -infected larvae treated with VOR combined with PP; FLU, C. neoformans -infected larvae treated with fluconazole alone; FLU+PP, C. neoformans -infected larvae treated with FLU combined with PP; AmB, C. neoformans -infected larvae treated with amphotericin B alone; AmB+PP, C. neoformans -infected larvae treated with AmB combined with PP; PP, C. neoformans -infected larvae treated with PP alone (* p < 0.05. **** p < 0.0001).

Article Snippet: All drugs, including itraconazole (ITR) (Lot No. s2476), voriconazole (VOR) (Lot No. s1442), posaconazole (POS) (Lot No., s1257), FLU (Lot No. s1331), PP (lot No.5816), and AmB (lot No.1636) were both purchased as powders from Selleck.cn, were dissolved in dimethyl sulfoxide or water (FLU) to a concentration of 6400ug/ml and stored at – 20°C.

Techniques: Infection, Saline, Injection

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease

doi: 10.1128/aac.01786-24

Figure Lengend Snippet: Experimental outline. C3H/HeN mice were infected with the bioluminescent T. cruzi JR-Luc strain (DTU I). At 21 days post-infection (dpi), they were treated once daily with 20 mg/kg posaconazole for 12 days (Materials and Methods). One cohort of mice was given no further treatment. A second cohort was treated with posaconazole (20 mg/kg) for 5 days each month, and a third was treated 1 day each week until the experimental end-point at 31 weeks post-infection (wpi). All mice were subjected to necropsy and analysis at this point.

Article Snippet: Posaconazole (Biosynth, Ltd.; 20 mg/kg) was administered orally via gavage with a flexible cannula in a vehicle of 5% DMSO (v/v) and 95% (0.5% hydroxypropyl methylcellulose and 0.4% Tween 80 in Milli-Q H 2 O).

Techniques: Infection

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease

doi: 10.1128/aac.01786-24

Figure Lengend Snippet: In vivo assessment of intermittent posaconazole treatment of T. cruzi -infected mice. (A) C3H/HeN mice were infected with the bioluminescent T. cruzi JR-Luc strain and monitored regularly by in vivo imaging (ventral images shown). As outlined , 21 dpi, mice were treated with posaconazole (20 mg/kg) once per day for 12 days. After this initial dosing, one group ( n = 5) received no further treatment (initial). A second group ( n = 5) was subsequently treated on five consecutive days each month (monthly), and a third group ( n = 5) was treated weekly with a single dose of 20 mg/kg posaconazole (weekly). The heat map is on a log10 scale and indicates intensity of bioluminescence from low (blue) to high (red). (B) Graphs showing the total body bioluminescence (ventral and dorsal imaging) (photons/second; p/s) of treated and non-treated mice throughout the experiment. The gray vertical bars indicate treatment periods.

Article Snippet: Posaconazole (Biosynth, Ltd.; 20 mg/kg) was administered orally via gavage with a flexible cannula in a vehicle of 5% DMSO (v/v) and 95% (0.5% hydroxypropyl methylcellulose and 0.4% Tween 80 in Milli-Q H 2 O).

Techniques: In Vivo, Infection, In Vivo Imaging, Imaging

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease

doi: 10.1128/aac.01786-24

Figure Lengend Snippet: End-point tissue and organ distribution of T. cruzi following various posaconazole treatment regimens. Two representative ex vivo images of tissues and organs harvested from mice in each cohort at the experimental end-point (31 wpi) (Materials and Methods). Tissues/organs were arranged as shown (inset, right). The heat map is on a log10 scale and indicates intensity of bioluminescence from low (blue) to high (red).

Article Snippet: Posaconazole (Biosynth, Ltd.; 20 mg/kg) was administered orally via gavage with a flexible cannula in a vehicle of 5% DMSO (v/v) and 95% (0.5% hydroxypropyl methylcellulose and 0.4% Tween 80 in Milli-Q H 2 O).

Techniques: Ex Vivo

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease

doi: 10.1128/aac.01786-24

Figure Lengend Snippet: Intermittent posaconazole treatment does not protect T. cruzi -infected mice from GI tract dysfunction. ( A ) Bar charts showing the impact of posaconazole treatment on GI transit time in C3H/HeN mice infected with the T. cruzi JR-Luc strain (non-infected mice, n = 4; non-treated mice, n = 6; each treatment group, n = 5). Transit times were established by monitoring the passage of the red dye tracer carmine (Materials and Methods). A 4 h (240 min) cut-off point for transit data acquisition was imposed for animal welfare reasons. Each dot represents a single mouse. Data are expressed as mean ± standard error of the mean (SEM). See for details on statistical analysis. ( B ) Bar chart showing the number of fecal pellets in the colon post-mortem (Materials and Methods) of non-infected mice, infected non-treated mice, and infected mice treated with posaconazole (initial, monthly, and weekly), as outlined in . Each dot represents a single mouse, with data expressed as mean ± SEM. Asterisks represent P -values for one-way analysis of variance, followed by Dunnett’s multiple comparison post-hoc test (* P < 0.05; ** P < 0.01; *** P < 0.001). All infected groups showed a significant difference to the non-infected group. There was no significant difference ( P > 0.05) between any of the treated groups and the non-treated group, as shown in the table.

Article Snippet: Posaconazole (Biosynth, Ltd.; 20 mg/kg) was administered orally via gavage with a flexible cannula in a vehicle of 5% DMSO (v/v) and 95% (0.5% hydroxypropyl methylcellulose and 0.4% Tween 80 in Milli-Q H 2 O).

Techniques: Infection, Comparison

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Intermittent suppressive posaconazole therapy is ineffective at mitigating cardiac and digestive tract pathologies in an experimental model of chronic Chagas disease

doi: 10.1128/aac.01786-24

Figure Lengend Snippet: Intermittent posaconazole treatment does not protect T. cruzi- infected mice from cardiac pathology. ( A ) Bar chart showing collagen content (blue area in Masson’s trichrome-stained sections) as a marker of cardiac fibrosis (Materials and Methods) in non-infected C3H/HeN mice ( n = 4), mice infected with T. cruzi JR-Luc strain, non-treated ( n = 6), and treated with posaconazole ( n = 5 per treatment cohort). Each dot corresponds to a single mouse, with data expressed as mean ± standard error of the mean (SEM). Asterisks represent P -values for one-way analysis of variance using Dunnett’s multiple comparison post-hoc test (* P < 0.05), with a significant difference between the non-infected group and all infected groups. There was no significant difference ( P > 0.05) between any of the treatment groups and the non-treated group. ( B–F ) Representative Masson’s trichrome-stained photomicrographs highlighting collagen (blue) in cardiac sections from posaconazole-treated and non-treated mice. Magnification 400×, scale bars = 100 µM. Bar charts show quantification of collagen content in individual mice from different groups, with each dot corresponding to the 15 randomly selected fields used for analysis and data expressed as mean ± SEM.

Article Snippet: Posaconazole (Biosynth, Ltd.; 20 mg/kg) was administered orally via gavage with a flexible cannula in a vehicle of 5% DMSO (v/v) and 95% (0.5% hydroxypropyl methylcellulose and 0.4% Tween 80 in Milli-Q H 2 O).

Techniques: Infection, Staining, Marker, Comparison

Journal: Molecular pharmaceutics

Article Title: Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole; In Vivo and In Vitro Assessment.

doi: 10.1021/acs.molpharmaceut.0c00471

Figure Lengend Snippet: Figure 2. CTD performance of posaconazole tablets at a 100-mg active dose compared to Noxafil

Article Snippet: Posaconazole (CAS 171228-49-2, >98% purity) was purchased from BOC Sciences (Shirley, NY, USA).

Techniques:

Journal: Molecular pharmaceutics

Article Title: Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole; In Vivo and In Vitro Assessment.

doi: 10.1021/acs.molpharmaceut.0c00471

Figure Lengend Snippet: Figure 3. Blood plasma concentration profiles for posaconazole formulations dosed in vivo to

Article Snippet: Posaconazole (CAS 171228-49-2, >98% purity) was purchased from BOC Sciences (Shirley, NY, USA).

Techniques: Clinical Proteomics, Concentration Assay, In Vivo

Journal: Frontiers in Molecular Biosciences

Article Title: A validated LC-ESI-MS/MS assay for simultaneous plasma quantification of 11 antimicrobials to support personalized dosing in critically ill children

doi: 10.3389/fmolb.2026.1745458

Figure Lengend Snippet: Representative chromatograms of double blank sample, IS of each ATB, LLOQ of 11 ATBs (Caspofungin, CAS; Cefazolin, CFZ; Cefmetazole, CMZ; Imipenem, IPM; Linezolid, LZD; Latamoxef, MOX; Meropenem, MEM; Posaconazole, POS; Tigecycline, TIG; Piperacillin, PRL; Voriconazole, VCZ; Caspofungin Acetate-d4, CAS-d4; Linezolid-d3, LZD-d3; Meropenem-d6, MEM-d6; Piperacillin-d5, PER-d5; Voriconazole-d3, VCZ-d3).

Article Snippet: Posaconazole (POS) was purchased from LGC Standards (Molsheim, France).

Techniques: